CONNECT WITH US
eCommerce

eCommerce

Phases Launches With Women-Focused Peptide Treatments

WWD logo

Published on

Add as a preferred source on Google
Phases Launches With Women-Focused Peptide Treatments

Phases, founded by husband-and-wife team Lana and Joseph Elie-Meyers, debuts with nine peptide-based treatments tailored to women’s health needs.

As the popularity of peptides continues to surge, Phases, a new telehealth platform by a Los Angeles-based husband-and-wife team, launches Tuesday.

For its take on the market, chief executive officer Lana Elie-Meyers and chief operating officer Joseph Elie-Meyers wanted Phases to focus on women’s evolving needs, from postpartum and perimenopause to menopause and beyond.

Lana Elie-Meyers, who previously founded floral marketplace Floom, which was acquired in 2025 by BloomNation, was inspired by her own postpartum health journey when she began exploring peptides after struggling with anxiety, eczema and brain fog. She recognized a gap in the market for women-focused care.

“I did find that once I finally took the jump, I had such incredible ROI. I’m also a healthy person. I’m pretty clean living. I exercise. I eat healthy. So we believe these are additive to a healthy lifestyle. We don’t sit in the position of these are miracle drugs that you can do nothing else in your life and see results from,” she said. “Through that experience, I just found that there was a gap in the market of everyone launching peptide options, but nothing felt unique to the female body. When I say the female body, it isn’t just that we go through such hormonal phases; it’s also that we have IBS, we have endometriosis, we have PCOS.”

Meanwhile, Joseph Elie-Meyers, a former civil rights litigator, has used his legal experience to navigate the regulatory landscape.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.